BHC

Bausch Health Companies Inc
NYSE

Real-time Quotes | Nasdaq Last Sale

15.22
-0.52
-3.30%
After Hours: 15.35 +0.13 +0.85% 19:31 09/24 EDT
OPEN
15.62
PREV CLOSE
15.74
HIGH
15.64
LOW
15.02
VOLUME
5.02M
TURNOVER
--
52 WEEK HIGH
31.97
52 WEEK LOW
11.15
MARKET CAP
5.40B
P/E (TTM)
-2.6309
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Bausch Health Announces VYZULTA® (Latanoprostene Bunod Ophthalmic Solution), 0.024%, is Now Approved In Seven Countries
Recent Access Wins Also Make VYZULTA Available To More Americans and Canadians SOPHIA ANTIPOLIS, France and LAVAL, Quebec, Sept. 24, 2020 /CNW/ -- Bausch Health Companies Inc.
CNW Group · 18h ago
Bausch Health VYZULTA expands coverage in Canada
Bausch + Lomb, a leading global eye health business of Bausch Health (BHC) announced that VYZULTA, which is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or
Seekingalpha · 18h ago
Bausch Health announces expanded coverage of Vyzulta in Canada
Bausch + Lomb, a leading global eye health business of Bausch Health (BHC) announced that VYZULTA, which is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or
Seekingalpha · 18h ago
Bausch Health' VYZULTA OK'd in Ukraine
On receiving regulatory approval in Ukraine, Bausch Health' (BHC) VYZULTA (latanoprostene bunod ophthalmic solution) is now marketed in total seven countries, including Argentina, Canada, Hong Kong, Mexico, Taiwan and the U.S. Medicare Part D coverage
Seekingalpha · 19h ago
Bausch + Lomb Announces Expanded Public Coverage For (Pr)VYZULTA (Latanoprostene Bunod Ophthalmic Solution 0.024% w/w) In Canada
PrVYZULTA® Added Under Alberta, Saskatchewan, Manitoba, New Brunswick, Nova Scotia, Newfoundland and Labrador, and Federal Non-Insured Health Benefits (NIHB)
Benzinga · 19h ago
Fintech Focus For September 24, 2020
Benzinga · 1d ago
Clearside Biomedical Announces Clinical Data Presentations at The Retina Society 2020 and Publication of XIPERE Data in Diabetic Macular Edema in Ophthalmology Retina
Presented the most robust aggregate dataset of suprachoroidal clinical injections demonstrating reliability and consistency of procedureALPHARETTA, Ga., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments
GlobeNewswire · 1d ago
Bausch Health Releases Annual Corporate Social Responsibility Report
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today released its annual Corporate Social Responsibility (CSR) Report, highlighting the Company's ongoing commitment to responsible, ethical and sustainable operations in 2019. In addition to outlining
PR Newswire · 1d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BHC. Analyze the recent business situations of Bausch Health Companies Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BHC stock price target is 26.76 with a high estimate of 50.00 and a low estimate of 17.00.
EPS
Institutional Holdings
Institutions: 351
Institutional Holdings: 202.85M
% Owned: 57.14%
Shares Outstanding: 354.99M
TypeInstitutionsShares
Increased
92
29.00M
New
48
3.86M
Decreased
112
38.99M
Sold Out
58
5.80M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.83%
Pharmaceuticals & Medical Research
-0.82%
Key Executives
Chairman/Chief Executive Officer/Director
Joseph Papa
Chief Financial Officer/Executive Vice President
Paul Herendeen
Corporate Executive
Thomas Appio
Corporate Executive
Joseph Gordon
Corporate Executive
William Humphries
Executive Vice President/General Counsel
Christina Ackermann
Independent Director
Richard DeSchutter
Lead Director
Thomas Ross
Independent Director
Richard De Schutter
Independent Director
D. Robert Hale
Independent Director
Argeris Karabelas
Independent Director
Sarah Kavanagh
Independent Director
John Paulson
Independent Director
Robert Power
Independent Director
Russel Robertson
Independent Director
Andrew Charles von Eschenbach
Independent Director
Andrew von Eschenbach
Independent Director
Amy Wechsler
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
09/22/2010
Dividend USD 16.77
09/23/2010
05/05/2010
Dividend USD 0.095
05/31/2010
02/24/2010
Dividend USD 0.09
03/04/2010
11/04/2009
Dividend USD 0.09
11/30/2009
08/06/2009
Dividend USD 0.09
08/28/2009
05/06/2009
Dividend USD 0.09
05/13/2009
02/26/2009
Dividend USD 0.375
03/06/2009
11/06/2008
Dividend USD 0.375
12/19/2008
08/13/2008
Dividend USD 0.375
08/21/2008
05/08/2008
Dividend USD 0.375
05/20/2008
03/13/2008
Dividend USD 0.375
03/25/2008
11/08/2007
Dividend USD 0.375
11/16/2007
08/08/2007
Dividend USD 0.375
08/16/2007
05/10/2007
Dividend USD 0.375
05/17/2007
03/15/2007
Dividend USD 0.375
03/22/2007
12/06/2006
Dividend USD 0.5
01/08/2007
11/09/2006
Dividend USD 0.125
11/20/2006
08/03/2006
Dividend USD 0.0775
08/15/2006
05/11/2006
Dividend USD 0.125
05/18/2006
03/23/2006
Dividend USD 0.125
04/05/2006
02/28/2006
Dividend USD 0.0775
03/14/2006
11/15/2005
Dividend USD 0.5
11/28/2005
11/04/2005
Dividend USD 0.0775
11/15/2005
08/04/2005
Dividend USD 0.0775
08/17/2005
03/10/2005
Dividend USD 0.0775
04/11/2005
12/29/2004
Dividend USD 0.0775
01/10/2005
06/30/2004
Dividend USD 0.0775
07/12/2004
03/03/2004
Dividend USD 0.0775
04/12/2004
12/19/2003
Dividend USD 0.0775
01/12/2004
01/04/2001
Dividend USD 0.0725
01/10/2001
10/04/1999
Dividend USD 0.07
10/08/1999
06/22/1999
Dividend USD 0.07
07/12/1999
03/22/1999
Dividend USD 0.07
04/12/1999
01/12/1999
Dividend USD 0.06
01/20/1999
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BHC
Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Bausch Health Companies Inc stock information, including NYSE:BHC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BHC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BHC stock methods without spending real money on the virtual paper trading platform.